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Abstract: Hyperglycaemia is prevalent in critical care, and tight control reduces mortality. 
Targeted glycaemic control can be achieved by frequent fitting and prediction of a 
modelled insulin sensitivity index, SI. However, this parameter varies significantly in the 
critically ill as their condition evolves. A 3-D stochastic model of hourly SI variability is 
constructed using retrospective data from 18 critical care patients. The model provides a 
blood glucose level probability distribution one hour following an intervention, enabling 
accurate prediction and more optimal glycaemic control. Copyright © 2006 IFAC 
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1. INTRODUCTION 
 
Hyperglycaemia and severe insulin resistance are 
prevalent in the critically ill, and tight control can 
reduce mortality up to 45% (Van den Berghe et al., 
2001). Chase et al. (2005a) clinically verified a 
targeted control algorithm that accounts for inter-
patient variability and evolving physiological 
condition. The adaptive control approach identifies 
patient dynamics, particularly insulin sensitivity, to 
determine the best control input. Hence better 
understanding and modelling of patient variability in 
the ICU can lead to better glycaemic management. 
 
Therefore, the ultimate goal of this study is to 
produce model-base blood glucose confidence bands 
to optimise glycaemic control. These bands are based 
on stochastic models developed from clinically 
observed model-based variations, and allow targeted 
control with user specified confidence on the 
glycaemic outcome.  
2. METHODS 
 
2.1 Glucose-Insulin System Model 
 
This study uses a patient-specific glucose-insulin 
system model from Chase et al. (2005a). It accounts 
for time-varying insulin sensitivity and endogenous 
glucose removal, and two saturation kinetics. 
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where G and I denote the glucose above an 
equilibrium level, GE, and the plasma insulin from an 
exogenous insulin input. Insulin utilization over time 
is Q, with effective insulin decay rate k. Endogenous 
glucose removal and insulin sensitivity are pG and SI. 
Insulin distribution volume is VI, and n is plasma 
insulin decay. External nutrition and insulin input are 
P(t) and uex(t). Michaelis-Menten saturation in 
plasma insulin disappearance and insulin-stimulated 
glucose removal are defined by αI and αG. 
       
Insulin sensitivity, SI, is the critical parameter that 
drives the dynamic system response to exogenous 
insulin. This value changes with the severity of 
illness, and thus captures the evolution of the 
patient’s insulin resistance and condition. Hence, 
identifying SI over time is critical to providing safe, 
tight glycaemic control. It will also enable better 
prediction of the outcome of an intervention. 
However, no such models or data currently exist. 
 
 
2.2 Stochastic Model 
 
Patient-specific parameters, pG and SI, are fitted to 
long term retrospective clinical data from 18 patients 
from a 201-patients data audit (Shaw et al., 2004). 
Parameter identification is performed with an 
integration-based method developed by Hann et al. 
(2005). Each patient record spans at least one day 
with data every three-hours or less. This cohort 
broadly represents the cross section of patients seen 
in the ICU, regarding medical condition, age, sex, 
APACHE II scores and mortality. 
 
Zero order piecewise linear functions are used to 
define pG and SI, with a discontinuity every two 
hours for pG and every hour for SI because greater 
variability in SI is previously identified (Hann et al., 
2005). Table 1 shows the parameter values (Chase et 
al., 2005a). 
 
Table 1: Generic parameter values 
 
Parameter Unit Value 
αG L/mU 1/65 
αI L/mU 0.0017 
n min-1 0.16 
k min-1 0.0198 
VI L 3.15 
 
The fitted pG and SI data reveals that the variability 
of both parameters is dependent on its present value. 
The distribution of fitted SI is shown by the dots in 
Figure 1. The probability distribution of potential SI, 
shown by the probability bands, clearly varies with 
its value across the horizontal axis.  
 
 
 
Figure 1: Fitted SI and probability intervals 
Thus, the variations in SI can be treated as a Markov 
process. A Markov process has the property that the 
conditional probability distribution of future states of 
the process, given the present state, depends only 
upon the current state. Therefore, using the Markov 
property of the stochastic behaviour of SI, the 
conditional probability distribution of SI n+1 taking on 
a value y can be calculated by knowing SI n = x: 
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Considering the fitted SI in a 2-D space, as shown in 
Figure 1, the joint probability function across the x-y 
(SI n - SI n+1) plane is defined by the fitted values 
shown by the dots whose coordinates are xi and yi, 
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Effectively, the 2-D joint probability function is the 
normalised summation of normal probability 
distribution functions ),;( 2
ixi
xx σφ  centred at 
individual data points. 
 
To illustrate a 3-D map in the mind, consider this 
numerical operation as a sand building exercise. If 
the first quadrant of the x-y (SI n - SI n+1) plane, as 
shown in Figure 1, is where the sand box is confined 
in, and that a pile of sand of a cubic unit is dropped 
onto every dot in Figure 1, then the resulted sand 
sculpture is the simple representation of the joint 
probability P(x, y) on the x-y (SI n - SI n+1) plane. In 
Equations (5)-(7), the variance σ  at each data point 
is a function of the local data density in a centred and 
orthonormalised space of x and y. Putting Equations 
(6) and (7) into Equation (5) normalises each 
),;( 2
ixi
xx σφ  and ),;( 2
iyi
yy σφ  in the positive 
domain. This, in the sand building exercise example, 
effectively puts boundaries along x = 0 and y = 0, 
confining sand to stay in the first quadrant, and 
therefore forces physiological validity in SI values. 
 
In Equation (4), the right hand side denominator can 
be calculated by integrating Equation (5) with respect 
to y. Hence, Equation (5) can be calculated: 
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Thus, knowing SI n = x at hour n, the probability of  
SI n+1 = y at hour n+1 can be calculated using 
Equations (8) and (9). The probability intervals 
shown in Figure 1 are also calculated from 
integrating Equation (8). Plotting Equation (8) across 
the x-y (SI n - SI n+1) plane, the resulting 3-D stochastic 
model is shown in Figures 2 and 3. 
 
The same numerical operations described in 
Equations (4)-(9) also apply to pG, producing similar 
results. However the probability density across the x-
y plane is highly concentrated along the line y = x, 
almost to the exclusion of other points. This result 
reinforces the idea that pG is effectively constant, 
even though patient specific (Hann et al., 2005). 
Hence, variability of pG is neglected in this study and 
pG = 0.01 used (Hann et al., 2005). 
 
 
 
Figure 2: Three-dimensional SI stochastic model 
 
 
 
 
Figure 3: Conditional probability distribution 
 
 
The stochastic parameter model developed can be 
integrated into the model of Equations (1)-(3), 
defining the blood glucose level probability 
distribution one hour following a known insulin 
and/or nutrition intervention. This distribution can 
then be used to adjust a target glucose value for the 
subsequent hour to ensure a probability of excedance 
for the resulting glucose level. The stochastic model 
therefore enables more knowledgeable predictions 
with defined probability distributions for the 
outcomes of glycaemic control inputs. 
 
 
2.3 Model Validation with Clinical Trial Data 
 
The stochastic model developed from the 18-patients 
cohort is evaluated on 8 clinical control trials (Wong 
et al., 2006). This data is independent from the cohort 
used to develop the stochastic model. The trials 
performed consisted of hourly cycles of the 
following steps: 
 
1. Measure blood glucose levels. 
2. Fit pG and SI to the measured blood glucose.  
3. Determine new control intervention to 
achieve a blood glucose target level. 
4. Implement control intervention. 
 
To asses the stochastic model, these 8 trials are 
numerically re-enacted with control interventions as 
given in the trial but with step 3 of the trial cycle 
modified to include the use of the model and 
confidence bands it generates for an intervention: 
 
3a. Generate potential SI probability intervals 
from the time-average identified SI of the 
fitted time interval using the stochastic 
model. 
3b. Calculate blood glucose confidence 
intervals with respect to the SI probability 
intervals using the numerical model in 
Equations (1)-(3). 
 
This test allows validation of the model in a clinical 
control scenario. The resulting outputs are validated 
based on how well the resulting clinical data fit the 
predicted distributions for the clinical trial patient. 
More specifically, it is a means of assessing whether, 
for example, the 90% confidence band delivered by 
the model captures 90% of the results. 
 
 
2.4 Application as Virtual Patient  
 
Finally, the model can be used to create virtual 
patients by using the Markov model to create a time-
varying profile for SI. In combination with the mdel 
of Equations (1)-(3) this stochastic model can then be 
used, with constraints on the limits for SI, to test or 
develop control protocols in simulated clinical trials. 
All that is required is an initial value and a validated 
stochastic model to ensure realistic behaviour for the 
virtual patients. 
 
 
3. RESULTS AND DISCUSSION 
 
3.1 Comparison to Clinical Trial Data  
 
Blood glucose probability intervals were produced at 
each control intervention in the 8 clinical trials and 
inter-quartile probability interval 
0.90 probability interval 
 
0.95 probability interval 
 
raw fitted SI
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compared to measured blood glucose levels one hour 
later. The results are shown in Table 2. Detailed 
results from Trial 4 are shown Figure 4. 
 
Table 2: Retrospective probabilistic assessment on 
clinical control trials 
Clinical 
control 
patients 
Number of 
interventions 
made 
Measurement 
error within 
inter-quartile 
probability 
interval 
Measurement 
error within 
0.90 
probability 
interval 
1 9 6 (67%) 9 (100%) 
2 9 5 (56%) 7 (78%) 
3 9 5 (56%) 8 (89%) 
4 9 5 (56%) 7 (78%) 
5 9 9 (100%) 9 (100%) 
6 9 9 (100%) 9 (100%) 
7 9 8 (89%) 9 (100%) 
8 23 16 (70%) 23 (100%) 
total 86 63 (73%) 81 (94%) 
 
 
The top panel of Figure 4 displays blood glucose, 
where the crosses are the actual clinical 
measurements with 7% measurement error, the solid 
line is the fitted blood glucose profile, and the circles 
are the most likely probabilistic blood glucose 
predictions following control interventions. The 90% 
band and inter-quartile probability ranges are shown 
by the bars. The bottom panel shows the fitted SI 
value, its most probable value, and its probabilistic 
bounds, as produced by the stochastic model. Note 
that only the prior hour’s value of SI is required to 
find the distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Simulated clinical control trial on Patient 4 
 
 
Patient 4’s blood glucose briefly dropped below 4 
mmol/L during the trial at approximately 360mins, 
which was not accounted for in the probabilistic 
forecast. Given the identified Patient 4 SI profile, 
different control interventions were explored. In 
particular, the SI stochastic model and 90% bounds 
are used to assist decision making. A comparison 
between the clinical trial and simulated new control 
intervention results is shown in Figure 5. 
 
Figure 5: Clinical trial vs. simulated new control 
results on Patient 4 
 
 
In Figure 5, the re-simulated control aimed to 
maintain the glycaemic levels above 4 mmol/L with 
90% probability. This use of the stochastic 
distribution from the model enabled the subsequent 
two hourly targets to be reset using that data. As a 
result, more aggressive interventions were issued in 
the first half of the simulated trial, achieving more 
tightly controlled glycaemic levels.  
 
The brief blood glucose excursion below 4 mmol/L 
was still unavoidable because the SI variation 
exceeded the 0.90 confidence limit at 300-360mins. 
However, a more vigorous remedy was taken at 360 
minutes in the simulated trial to obtain a 0.90 
confidence in blood glucose above 4 mmol/L in an 
hour. This first intervention was a large feed change 
as seen in Figure 4. It was followed by an aggressive 
insulin bolus to counter the sudden feed change the 
hour prior. Overall, the SI stochastic model can be 
used to deliver tighter, safer glycaemic management 
and improve control intervention selection. 
 
Across all 8 patients, the SI stochastic model 
successfully captures the identified SI variation trend, 
accounting for 94% of measurements over time 
within the 0.90 confidence band, and 73% with a 
0.50 confidence. Hence, the model may be slightly 
conservative in this respect where the 7% 
measurement error is considered. 
 
However, if just the measured values are used from 
the trials the results are closer to exact. Specifically, 
48% of explicit measurement values were in the 0.50 
band and 87% were in the 0.90 band. Thus, without 
accounting for measurement error the model is 
slightly in error, which may be due to the limited 
number of measurements, the first order Markov 
model employed, or both. 
 
Overall, it is worth noting that when SI increases, the 
blood glucose level probability interval tightens, as 
seen in Figures 1-2. The wider range of uncertainties 
in blood glucose levels associated with low SI reflects 
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the risk of hypoglycaemic events for highly insulin 
resistant patients under intensive insulin therapy 
(Amiel et al., 1987). This situation was specifically 
seen in Patient 4, whose identified SI profile is in the 
lower physiological range. 
 
 
3.2 Virtual Trial Application and Analysis 
 
“Virtual patients” with pG and SI following the 
stochastic behaviour of the Markov model developed 
reflect typical critical care patient conditions. A 
virtual cohort of n = 200 patients was created and 
tested in simulated trials. Initial conditions for these 
virtual patients, including starting blood glucose 
levels, initial SI levels, insulin infusion, dextrose 
infusion etc., were randomly chosen to represent 
typical critical care situations. Resulting blood 
glucose probability intervals from control inputs are 
produced with each control intervention. The 
simulated trials each span 24 hours. Therefore, 23 
hourly blood glucose measurements (excluding the 
starting blood glucose levels) were analysed against 
the probability intervals. The results from the 
simulated trials are summarised in Table 3. 
 
 
Table 3: Virtual patient trials summary 
 
Glucose < 4 
mmol/L 
Glucose in  
50% band 
(%) 
Glucose in  
90% band 
(%) 
Max 22% 96% 100 
Mean 2.5% 77% 95% 
Min 0% 52% 78% 
SD 4% 9% 4.5% 
 
 
The virtual cohort produced results that are similar to 
the 8 clinical trials. The inter-quartile confidence 
intervals covered 77% of blood glucose 
measurements, and the 0.90 confidence intervals 
covered 95%. The defined hypoglycaemic level for 
the trials was 4 mmol/L.  
 
All control interventions maintained a minimum of 
0.90 confidence level in the resulting blood glucose 
levels being above 4 mmol/L. Across the 200 virtual 
patients cohort, 2 measurements (0.04%) fell below 3 
mmol/L, and 111 (2.5%) fell below 4 mmol/L. These 
slightly hypoglycaemic events all occurred when SI 
took a sudden rise that exceeded the 0.90 probability 
intervals in SI.  
 
The loss of control with large swings outside the 
90% likelihood of occurrence, further illustrates the 
meaning of this bound. In particular, the size of such 
swings, especially at low insulin sensitivity, indicates 
the size of the change required to be outside the 90% 
likelihood of occurrence. In contrast, the width of 
these bounds also indicates that 10% of the time 
patients can take sudden, quite drastic swings in 
insulin sensitivity. These quite drastic swings would 
be due to equally significant changes in patient 
condition. Hence, the metric may be worth 
monitoring on its own as a guide to patient condition. 
From a control standpoint, the targeted, confidence 
interval based control algorithm was able to maintain 
blood glucose levels within the 4-6 mmol/L band 
70% of the time once the blood glucose levels were 
brought into this range. This value exceeds clinical 
simulations without confidence bands (Wong et al., 
2005). For those patients whose blood glucose levels 
were reduced to 4-6 mmol/L (n = 159) during the 24-
hour simulated trial, 125 (78.62%) stayed in the band 
more than 50% of the time, and 78 (50.94%) stayed 
in the band more than 75% of the time. 
 
More notably, out of the cohort of 200 virtual 
patients, 41 (20.50%) never achieved normoglycemia  
in the 4-6 mmol/L band at any instance during the 24 
hours trial due to insulin resistance and insulin effect 
saturation. These patients have virtual SI profiles 
generally in the very low physiological range. 
Consequently, insulin-stimulated glucose removal 
was constantly saturated with high insulin doses, and 
the blood glucose confidence bands are also wide.  
 
These results indicated that to always maintain a 0.90 
confidence level against a hypoglycaemic event, the 
achievable blood glucose reduction is limited in 
some cases. In particular, very low insulin sensitivity 
and wide 0.90 bands will hinder the ability to remain 
in the 4-6 mmol/L band under control, while also 
ensuring a 90% confidence of no hypoglycaemic 
events. As a result, the glucose levels are higher. 
These results match clinical observations that blood 
glucose levels under control are more volatile in 
highly insulin resistant patients (Chase et al., 2005b; 
Hann et al., 2005; Wong et al., 2006). 
 
The average number of hours taken for the blood 
glucose levels to be reduced to within 4-6 mmol/L 
from the start of the trial was 8.3 (SD ±8.91) hours. 
Hence, the time taken to get into the band for a 
hyperglycaemic patient can be quite high if they are 
highly insulin resistant. This result highlights the 
need to take early action at the emergence of 
hyperglycaemia in critical care.   
 
 
3.3 Results and Discussion Summary 
 
The glucose-insulin system model, together with the 
integral-based parameter identification, can 
effectively capture critical care patient behaviour. In 
addition, the stochastic model further enhances the 
ability to predict, as well as imitate, typical critical 
care patient dynamics. The incorporation of the 
stochastic model into the numerical glucose-insulin 
system can also be used to create “virtual patients”, 
creating a platform to experiment with different 
clinical control protocols based on clinically 
observed patient dynamics and evolution.  
       
Overall, higher identified SI levels result in tighter 
blood glucose probability intervals, making tighter 
control easier with less control effort. It is worth 
noting that less critically ill patients, by APACHE II 
or other score, are also typically less insulin resistant 
and hyperglycaemic (e.g. Christiansen et al., 2004; 
Mentula et al., 2005). Therefore, a less critically ill 
cohort is potentially much more likely to be easier to 
control in terms of variability. This result could thus 
be used to help compare results of different protocols 
on different types of patient cohorts.   
 
 
4. CONCLUSIONS 
 
The stochastic model presented defines the variation 
of critical care patient insulin sensitivity for the 
system model presented. As a result, the distribution 
of blood glucose levels one hour following a known 
insulin and/or nutrition intervention can be 
determined and used to enhance control, by enabling 
more knowledgeable and accurate prediction. The 
stochastic model thus acts as a tool to assist clinical 
intervention decisions, maximising the probability of 
achieving the desired tight glycaemic regulation 
while maintaining patient safety. The same stochastic 
model can also be used to create realistic, validated 
virtual patients for developing new control protocols. 
 
More generally, application of this model also offers 
new insights. In particular, the model shows that less 
critically ill cohorts, who are also less insulin 
resistant, have tighter variation in insulin sensitivity. 
Such cohorts would be easier to control and shed 
light on the different results obtained in landmark 
glycaemic control studies with very different cohorts 
in terms of APACHE II score and level of critical 
illness. Overall, the model allows the impact of 
control inputs on blood glucose levels to be 
statistically assessed, providing further confidence in 
the effectiveness of the control protocol utilised 
against evolving patient dynamics. 
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